<p>MIRA Pharmaceuticals（纳斯达克代码：MIRA - 获取免费报告）在周六发布给投资者的研究报告中，被华尔街 Zen 的分析师将评级从 “持有” 下调至 “卖出”。</p>
<p>获取 <strong>MIRA Pharmaceuticals</strong> 的提醒：</p>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 MIRA Pharmaceuticals 股票的 “卖出（e+）” 评级。根据 MarketBeat 的数据，一位研究分析师对该股票给予了卖出评级，该公司的平均评级为 “卖出”。</p>
<p><strong>阅读我们关于 MIRA 的最新股票报告</strong></p>
<h2>MIRA Pharmaceuticals 价格表现</h2>
<p>MIRA 股票在周五开盘价为 1.39 美元。该公司的市值为 5821 万美元，市盈率为-0.91，贝塔值为 1.72。公司 50 日移动平均线为 1.42 美元，200 日移动平均线为 1.40 美元。MIRA Pharmaceuticals 的 52 周最低价为 0.73 美元，52 周最高价为 2.45 美元。</p>
<p>MIRA Pharmaceuticals（纳斯达克代码：MIRA - 获取免费报告）最后一次发布季度收益数据是在 11 月 13 日星期四。该公司报告本季度每股收益为（1.18 美元），低于市场共识预期的（0.11 美元）1.07 美元。股票分析师预计 MIRA Pharmaceuticals 在当前财政年度将发布-0.6 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该公司的持股。国际资产投资管理公司在第二季度收购了 MIRA Pharmaceuticals 的新股份，价值 42,000 美元。Two Sigma Investments LP 在第三季度将其在 MIRA Pharmaceuticals 的持股提高了 129.8%。Two Sigma Investments LP 目前拥有 45,703 股该公司的股票，价值 62,000 美元，此前在该期间额外收购了 25,816 股。XTX Topco Ltd 在第二季度收购了 MIRA Pharmaceuticals 的新股份，价值约 26,000 美元。Creative Planning 在第二季度购买了 MIRA Pharmaceuticals 的新股份，价值约 27,000 美元。最后，First American Bank 在第三季度将其在 MIRA Pharmaceuticals 的持股提高了 150.0%。First American Bank 目前拥有 50,000 股该公司的股票，价值 68,000 美元，此前在上个季度额外购买了 30,000 股。目前，35.16% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 MIRA Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>MIRA Pharmaceuticals, Inc 是一家处于临床前阶段的制药开发公司，拥有两个神经科学项目，针对一系列神经和精神疾病。该公司拥有 Ketamir-2 的美国、加拿大和墨西哥独占权，这是一种正在研究的口服氯胺酮类似物，旨在为抗药性抑郁症、伴有自杀意念的重度抑郁症和创伤后应激障碍患者提供超快速的抗抑郁效果。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 MIRA Pharmaceuticals</li>
<li>如何在购买前评估一只股票</li>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>如何利用分析师评级进行交易</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>3 只可以帮助应对通货膨胀的食品杂货股票</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MIRA Pharmaceuticals 吗？</h2>
<p>在考虑 MIRA Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MIRA Pharmaceuticals 并不在名单上。</p>
<p>虽然 MIRA Pharmaceuticals 目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MIRA

<p>Wall Street Zen 将 MIRA Pharmaceuticals (NASDAQ:MIRA) 的评级从 “持有” 下调至 “卖出”。Weiss Ratings 也重申了 “卖出” 评级。MIRA 的股票开盘价为 1.39 美元，市值为 5821 万美元。分析师预计该财年的每股收益为 -0.6。机构投资者已调整其持股比例，机构持股占比为 35.16%。MIRA 作为一家处于临床前阶段的制药公司，专注于神经系统疾病。尽管评级为卖出，分析师建议其他股票作为更好的投资选择</p>

<p>MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) was downgraded by analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note issued to investors on Saturday.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals（纳斯达克代码：MIRA - 获取免费报告）在周六发布给投资者的研究报告中，被华尔街 Zen 的分析师将评级从 “持有” 下调至 “卖出”。</p>
</div><p>Get <strong>MIRA Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>MIRA Pharmaceuticals</strong> 的提醒：</p>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of MIRA Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 MIRA Pharmaceuticals 股票的 “卖出（e+）” 评级。根据 MarketBeat 的数据，一位研究分析师对该股票给予了卖出评级，该公司的平均评级为 “卖出”。</p>
</div><p><strong>Read Our Latest Stock Report on MIRA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 MIRA 的最新股票报告</strong></p>
</div><h2>MIRA Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>MIRA Pharmaceuticals 价格表现</h2>
</div><p>MIRA stock opened at $1.39 on Friday. The stock has a market capitalization of $58.21 million, a price-to-earnings ratio of -0.91 and a beta of 1.72. The company has a 50-day moving average of $1.42 and a two-hundred day moving average of $1.40. MIRA Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $2.45.</p>
<div class="lb-trans"><p>MIRA 股票在周五开盘价为 1.39 美元。该公司的市值为 5821 万美元，市盈率为-0.91，贝塔值为 1.72。公司 50 日移动平均线为 1.42 美元，200 日移动平均线为 1.40 美元。MIRA Pharmaceuticals 的 52 周最低价为 0.73 美元，52 周最高价为 2.45 美元。</p>
</div><p>MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Equities analysts expect that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals（纳斯达克代码：MIRA - 获取免费报告）最后一次发布季度收益数据是在 11 月 13 日星期四。该公司报告本季度每股收益为（1.18 美元），低于市场共识预期的（0.11 美元）1.07 美元。股票分析师预计 MIRA Pharmaceuticals 在当前财政年度将发布-0.6 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in MIRA Pharmaceuticals during the second quarter worth $42,000. Two Sigma Investments LP lifted its holdings in shares of MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company's stock worth $62,000 after acquiring an additional 25,816 shares during the period. XTX Topco Ltd acquired a new stake in shares of MIRA Pharmaceuticals during the 2nd quarter valued at about $26,000. Creative Planning bought a new stake in MIRA Pharmaceuticals in the second quarter valued at about $27,000. Finally, First American Bank raised its position in MIRA Pharmaceuticals by 150.0% in the third quarter. First American Bank now owns 50,000 shares of the company's stock worth $68,000 after purchasing an additional 30,000 shares in the last quarter. 35.16% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。国际资产投资管理公司在第二季度收购了 MIRA Pharmaceuticals 的新股份，价值 42,000 美元。Two Sigma Investments LP 在第三季度将其在 MIRA Pharmaceuticals 的持股提高了 129.8%。Two Sigma Investments LP 目前拥有 45,703 股该公司的股票，价值 62,000 美元，此前在该期间额外收购了 25,816 股。XTX Topco Ltd 在第二季度收购了 MIRA Pharmaceuticals 的新股份，价值约 26,000 美元。Creative Planning 在第二季度购买了 MIRA Pharmaceuticals 的新股份，价值约 27,000 美元。最后，First American Bank 在第三季度将其在 MIRA Pharmaceuticals 的持股提高了 150.0%。First American Bank 目前拥有 50,000 股该公司的股票，价值 68,000 美元，此前在上个季度额外购买了 30,000 股。目前，35.16% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About MIRA Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 MIRA Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals, Inc 是一家处于临床前阶段的制药开发公司，拥有两个神经科学项目，针对一系列神经和精神疾病。该公司拥有 Ketamir-2 的美国、加拿大和墨西哥独占权，这是一种正在研究的口服氯胺酮类似物，旨在为抗药性抑郁症、伴有自杀意念的重度抑郁症和创伤后应激障碍患者提供超快速的抗抑郁效果。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MIRA Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How to trade using analyst ratings</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 MIRA Pharmaceuticals</li>
<li>如何在购买前评估一只股票</li>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>如何利用分析师评级进行交易</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>3 只可以帮助应对通货膨胀的食品杂货股票</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MIRA Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MIRA Pharmaceuticals 吗？</h2>
</div><p>Before you consider MIRA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MIRA Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MIRA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MIRA Pharmaceuticals 并不在名单上。</p>
</div><p>While MIRA Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MIRA Pharmaceuticals 目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MIRA Pharmaceuticals（纳斯达克代码：MIRA）在 Wall Street Zen 的评级被下调至卖出